ERBB2 and ovarian cancer: However, the poor response rate of the single agent trastuzumab, a monoclonal humanized anti-HER2 antibody was reported in 2003 in recurrent ovarian cancers showing HER2 overexpression (forty-one recurrent ovarian cancer cases, including seven clear cell types) [19].